Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT07001995
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • limertinib — DRUG
    limertinib 80 mg
  • etoposide and carboplatin — DRUG
    etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV

Study Details

This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.

Key Dates

First listed
Jun 3, 2025
Start date
May 1, 2026
Status verified
Mar 2026
Primary completion
Dec 30, 2027
Completion
Dec 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental group
    Limertinib Carboplatin Etoposide

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: Time from first subject dose to study completion, or up to 36 month ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies